Viking Therapeutics
VKTX
S$42.37
Share price
-0.87%
Change (1 day)
-48.45%
Change (1 year)
Categories
Viking Therapeutics (VKTX) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : S$25.84 Million
According to Viking Therapeutics 's latest financial reports the company's total liabilities are S$25.84 Million. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Viking Therapeutics - Total liabilities on balance sheet (from 2014 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | S$38.11 M | 43.8% |
| 2023-12-31 | S$26.5 M | -14.8% |
| 2022-12-31 | S$31.11 M | 162.17% |
| 2021-12-31 | S$11.86 M | -26.22% |
| 2020-12-31 | S$16.08 M | 67.16% |
| 2019-12-31 | S$9.62 M | 54.39% |
| 2018-12-31 | S$6.23 M | -46.17% |
| 2017-12-31 | S$11.57 M | 23.22% |
| 2016-12-31 | S$9.39 M | -1.06% |
| 2015-12-31 | S$9.49 M | -71.45% |
| 2014-12-31 | S$33.26 M | 5990.9% |
| 2013-12-31 | S$0.54 M | 323.6% |
| 2012-12-31 | S$0.12 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Ultragenyx Pharmaceutical RARE | S$1.49 B | 5,681.72% | 🇺🇸 USA |
 Repligen
RGEN | S$1.11 B | 4,217.11% | 🇺🇸 USA |